MetaVia Inc. (NASDAQ:MTVA – Free Report) – Investment analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of MetaVia in a research report issued to clients and investors on Monday, December 30th. HC Wainwright analyst E. Arce expects that the company will earn ($3.87) per share for the year. HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.91) per share. HC Wainwright also issued estimates for MetaVia’s Q1 2025 earnings at ($0.65) EPS, Q2 2025 earnings at ($0.57) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.65) EPS, FY2027 earnings at ($4.27) EPS and FY2028 earnings at ($4.58) EPS.
MetaVia Price Performance
Shares of NASDAQ MTVA opened at $1.98 on Tuesday. MetaVia has a 1 year low of $1.51 and a 1 year high of $6.75.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
Read More
- Five stocks we like better than MetaVia
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Must-Hold Stocks with Double-Digit Upside for 2025
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Micron: Why Now Is the Time to Be Brave
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Stocks That Wall Street Insiders Can’t Stop Buying
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
